Granted Patent B2

US 6,864,257 · App. 10/200,510 · Granted Mar 8, 2005

Assignee: Sepracor Inc.

Abstract

Claims (7)

1. A method of inducing an effect selected from the group consisting of a hypnotic effect, a sedative effect and a tranquilizing effect, in a human in need of said induction, comprising administering to the human an effective quantity of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine, or a pharmaceutically acceptable salt thereof, in the form of its dextrorotatory isomer and essentially free of its levorotatory isomer.

2. The method according to claim 1 , wherein said administering step comprises administering a pharmaceutical composition comprising an effective amount of said 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)-carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine, or a pharmaceutically acceptable salt thereof, in the form of its dextrorotatory isomer and essentially free of its levorotatory isomer, and a pharmaceutically acceptable carrier.

3. The method according to claim 1 , wherein the pharmaceutically acceptable salt is a salt of a mineral acid, or a substituted derivative thereof, selected from the group consisting of hydrochlorides, sulfates, nitrates, and phosphates.

4. The method according to claim 1 , wherein the pharmaceutically acceptable salt is a salt of an organic acid, or a substituted derivative thereof, selected from the group consisting of acetates, propionates, succinates, benzoates, fumarates, tartrates, theophyllineacetates, salicylates, and phenolphthalinates.

5. The method according to claim 1 , wherein the effective quantity is from about 2.5 mg to about 15 mg per day.

6. The method according to claim 2 ,wherein the pharmaceutically acceptable carrier comprises a diluent.

7. The method according to claim 2 wherein the composition is administered orally, rectally or parenterally.

Assignments (1)

Priority Claims (1)

Continuity (9)